表紙
市場調査レポート

虚血性発作:パイプライン製品の分析

Ischemic Stroke - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 253642
出版日 ページ情報 英文 277 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
虚血性発作:パイプライン製品の分析 Ischemic Stroke - Pipeline Review, H2 2015
出版日: 2015年09月30日 ページ情報: 英文 277 Pages
概要

虚血性発作とは、脳の一部で血液循環が突然停止し、神経機能の損傷につながるという疾患です。主な徴候・症状には、複視やめまい、視野狭窄、顔面のたるみ(麻痺)、失語症、意識水準の突然の低下などがあります。抗凝固剤を投与して、虚血性発作の原因となっている血餅を溶解すること、また薬剤療法による脳腫脹の除去・制御が、主な治療法となります。

当レポートでは、世界各国での虚血性発作治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

虚血性発作の概要

治療薬の開発

  • 虚血性発作向けパイプライン製品:概要
  • 虚血性発作向けパイプライン製品:比較分析

各企業で開発中の虚血性発作治療薬

大学/研究機関で研究中の虚血性発作治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

虚血性発作治療薬:開発中の製品の一覧(企業別)

虚血性発作治療薬:研究中の製品の一覧(大学/研究機関別)

虚血性発作治療薬の開発に従事している企業

  • BioTime, Inc.
  • Athersys, Inc.
  • GlaxoSmithKline plc
  • 第一三共
  • Merck & Co., Inc.
  • FibroGen, Inc.
  • Panacea Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • 三菱田辺製薬
  • Celgene Corporation
  • Neuralstem, Inc.
  • Mesoblast Limited
  • Torrent Pharmaceuticals Limited
  • Pluristem Therapeutics Inc.
  • Huons Co., Ltd.
  • NeuroVive Pharmaceutical AB
  • Digna Biotech, S.L.
  • AGY Therapeutics, Inc.
  • Angion Biomedica Corp.
  • Concert Pharmaceuticals, Inc.
  • Virogenomics, Inc.
  • Stemedica Cell Technologies, Inc.
  • Shin Poong Pharm Co., Ltd.
  • Tarix Pharmaceuticals LTD.
  • International Biotechnology Center Generium
  • MediaPharma s.r.l.

虚血性発作:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 硫酸ボラパクサール
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • 塩酸プラスグレル
  • GSK-249320
  • MultiStem
  • cenplacel-L
  • レボミルナシプランER(持続放出)
  • ダルファムプリジンER
  • dextran 40
  • 間葉系骨髄細胞
  • フィルグラスチム
  • HU-010
  • ピノセムブリン
  • 自家骨髄由来間葉系幹細胞
  • NSI-566
  • 自家骨髄由来CD34+幹細胞
  • SP-8203
  • FG-4539
  • PAN-811
  • BB-3
  • TXA-127
  • CEP-41750
  • 虚血性発作向けPLX細胞
  • NVP-014
  • 虚血性発作向けAGY-221阻害葉小分子
  • TRC-051384
  • GNR-014
  • アポトランスフェリン
  • 発作の治療法
  • T-33
  • 虚血性発作・肝不全向けグルタチオンペルオキシダーゼ活性化用小分子
  • 虚血性発作向け幹細胞治療
  • AB-144
  • 虚血性発作向けtPA阻害葉モノクローナル抗体
  • 虚血性発作向けナトリウム・hERGチャネル阻害用小分子
  • 虚血性発作・心筋梗塞向けSir2タンパク質阻害用薬剤
  • パーキンソン病・虚血性発作向け間葉系前駆細胞の自家移植
  • CNB-001
  • 塩酸メクリジン
  • StromAb
  • SMTP-7
  • 虚血性発作向けナトリウムチャネル阻害用小分子
  • 虚血性発作向けCaMKII阻害用小分子
  • RTL-551
  • DB-017
  • MPHE-001A
  • C-10068
  • 虚血性発作向けタンパク質
  • 虚血性発作向けAGY-220阻害用小分子
  • 虚血性発作向けAGY-218阻害用小分子
  • 虚血性発作向けAGY-207阻害用小分子
  • 虚血性発作向けキナーゼ阻害用小分子
  • 虚血性発作プログラム

虚血性発作治療薬:パイプライン製品の最新動向

虚血性発作治療薬:開発が休止状態の製品

虚血性発作治療薬:開発が中止された製品

虚血性発作関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7071IDB

Summary

Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H2 2015', provides an overview of the Ischemic Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ischemic Stroke Overview
  • Therapeutics Development
    • Pipeline Products for Ischemic Stroke - Overview
    • Pipeline Products for Ischemic Stroke - Comparative Analysis
  • Ischemic Stroke - Therapeutics under Development by Companies
  • Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes
  • Ischemic Stroke - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ischemic Stroke - Products under Development by Companies
  • Ischemic Stroke - Products under Investigation by Universities/Institutes
  • Ischemic Stroke - Companies Involved in Therapeutics Development
    • AB Science SA
    • Acticor Biotech
    • advanceCor GmbH
    • Angion Biomedica Corp.
    • AstraZeneca Plc
    • Athersys, Inc.
    • biOasis Technologies Inc.
    • Biogen, Inc.
    • BioTime, Inc.
    • D-Pharm Ltd.
    • Daiichi Sankyo Company, Limited
    • DiaMedica Inc.
    • Digna Biotech, S.L.
    • Genervon Biopharmaceuticals, LLC
    • Glialogix, Inc.
    • Glucox Biotech AB
    • Grifols, S.A.
    • Huons Co., Ltd.
    • International Stem Cell Corporation
    • JN-International Medical Corporation
    • Laboratoires Pierre Fabre SA
    • Lumosa Therapeutics Co., Ltd.
    • MediaPharma s.r.l.
    • Mitsubishi Tanabe Pharma Corporation
    • Neuralstem, Inc.
    • Neurotec Pharma SL
    • NeuroVive Pharmaceutical AB
    • NoNO, Inc.
    • Panacea Pharmaceuticals, Inc.
    • Pharmicell Co., Ltd.
    • PhytoHealth Corporation
    • Remedy Pharmaceuticals, Inc.
    • ReNeuron Group Plc
    • SanBio, Inc.
    • Saneron CCEL Therapeutics, Inc.
    • Simcere Pharmaceutical Group
    • Stemedica Cell Technologies, Inc.
    • SynZyme Technologies, LLC
    • The International Biotechnology Center (IBC) Generium
    • TikoMed AB
    • vasopharm GmbH
    • Vicore Pharma AB
    • Virogenomics, Inc.
  • Ischemic Stroke - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
    • ACT-017 - Drug Profile
    • alteplase biosimilar - Drug Profile
    • BB-3 - Drug Profile
    • BSc-2118 - Drug Profile
    • C-21 - Drug Profile
    • Cerecellgram-Stroke - Drug Profile
    • CNB-001 - Drug Profile
    • DB-017 - Drug Profile
    • DM-199 - Drug Profile
    • Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile
    • DS-1040 - Drug Profile
    • GLX-1112 - Drug Profile
    • glyburide - Drug Profile
    • GM-602 - Drug Profile
    • GXNPC-1 - Drug Profile
    • HBN-1 - Drug Profile
    • HU-010 - Drug Profile
    • Human Plasmin - Drug Profile
    • Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
    • ISC-hpNSC - Drug Profile
    • levomilnacipran hydrochloride ER - Drug Profile
    • LT-3001 - Drug Profile
    • Lysimab - Drug Profile
    • masitinib - Drug Profile
    • Memantine Nitrone - Drug Profile
    • Mesenchymal Stem Cells - Drug Profile
    • MP-124 - Drug Profile
    • MPHE-001A - Drug Profile
    • MTfp-siRNA - Drug Profile
    • MultiStem - Drug Profile
    • NA-1 - Drug Profile
    • natalizumab - Drug Profile
    • NSI-566 - Drug Profile
    • NTKC-005 - Drug Profile
    • NVP-014 - Drug Profile
    • NVX-208 - Drug Profile
    • PAN-811 - Drug Profile
    • Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
    • PHN-014 - Drug Profile
    • Pinocembrin - Drug Profile
    • Polyglactin 370 for Ischemic Stroke - Drug Profile
    • PR-15 - Drug Profile
    • prasugrel hydrochloride - Drug Profile
    • Protein for Ischemic Stroke - Drug Profile
    • Protein for Ischemic Stroke - Drug Profile
    • Protein for Ischemic Stroke - Drug Profile
    • Recombinant Peptide for Ischemic Stroke - Drug Profile
    • Recombinant Plasmin - Drug Profile
    • Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia - Drug Profile
    • Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
    • ReN-001 - Drug Profile
    • RTL-551 - Drug Profile
    • SB-623 - Drug Profile
    • SIM-071201 - Drug Profile
    • Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
    • Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile
    • Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
    • Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
    • Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile
    • Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile
    • Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile
    • Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile
    • SMTP-7 - Drug Profile
    • StromAb - Drug Profile
    • T-33 - Drug Profile
    • TF-0023 - Drug Profile
    • THR-18 - Drug Profile
    • ticagrelor - Drug Profile
    • TM-700 - Drug Profile
    • TPAi-14 - Drug Profile
    • TPAi-23 - Drug Profile
    • TS-01 - Drug Profile
    • TXA-127 - Drug Profile
    • TXA-302 - Drug Profile
    • UCCB-01144 - Drug Profile
    • Vaccine to Target NMDAR1 for Ischemic Stroke - Drug Profile
    • VACNO - Drug Profile
    • VAS-2870 - Drug Profile
  • Ischemic Stroke - Recent Pipeline Updates
  • Ischemic Stroke - Dormant Projects
  • Ischemic Stroke - Discontinued Products
  • Ischemic Stroke - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ischemic Stroke, H2 2015
  • Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Ischemic Stroke - Pipeline by AB Science SA, H2 2015
  • Ischemic Stroke - Pipeline by Acticor Biotech, H2 2015
  • Ischemic Stroke - Pipeline by advanceCor GmbH, H2 2015
  • Ischemic Stroke - Pipeline by Angion Biomedica Corp., H2 2015
  • Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2015
  • Ischemic Stroke - Pipeline by Athersys, Inc., H2 2015
  • Ischemic Stroke - Pipeline by biOasis Technologies Inc., H2 2015
  • Ischemic Stroke - Pipeline by Biogen, Inc., H2 2015
  • Ischemic Stroke - Pipeline by BioTime, Inc., H2 2015
  • Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2015
  • Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2015
  • Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2015
  • Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
  • Ischemic Stroke - Pipeline by Glialogix, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2015
  • Ischemic Stroke - Pipeline by Grifols, S.A., H2 2015
  • Ischemic Stroke - Pipeline by Huons Co., Ltd., H2 2015
  • Ischemic Stroke - Pipeline by International Stem Cell Corporation, H2 2015
  • Ischemic Stroke - Pipeline by JN-International Medical Corporation, H2 2015
  • Ischemic Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
  • Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
  • Ischemic Stroke - Pipeline by MediaPharma s.r.l., H2 2015
  • Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
  • Ischemic Stroke - Pipeline by Neuralstem, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Neurotec Pharma SL, H2 2015
  • Ischemic Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
  • Ischemic Stroke - Pipeline by NoNO, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2015
  • Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2015
  • Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
  • Ischemic Stroke - Pipeline by ReNeuron Group Plc, H2 2015
  • Ischemic Stroke - Pipeline by SanBio, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2015
  • Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
  • Ischemic Stroke - Pipeline by SynZyme Technologies, LLC, H2 2015
  • Ischemic Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
  • Ischemic Stroke - Pipeline by TikoMed AB, H2 2015
  • Ischemic Stroke - Pipeline by vasopharm GmbH, H2 2015
  • Ischemic Stroke - Pipeline by Vicore Pharma AB, H2 2015
  • Ischemic Stroke - Pipeline by Virogenomics, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2015
  • Ischemic Stroke - Dormant Projects, H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..1), H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..2), H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..3), H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..4), H2 2015
  • Ischemic Stroke - Discontinued Products, H2 2015
  • Ischemic Stroke - Discontinued Products (Contd..1), H2 2015
  • Ischemic Stroke - Discontinued Products (Contd..2), H2 2015

List of Figures

  • Number of Products under Development for Ischemic Stroke, H2 2015
  • Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top